Davis Polk advised the representatives of the several underwriters in the offering.Recursion Pharmaceuticals, Inc. executed its $500 million initial public offering of 27,878,787 shares of Class A…
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here
